Cover Image
Market Research Report
Product code 
1064083

Plant-based Biologics and Expression Systems Market by Type of Product (Biosimilars, Cell Therapies, Gene Therapies, Monoclonal Antibodies, Vaccines and Others), Type of Plant, Type of Service, Type of Expression System

Published: | Roots Analysis | 155 Slides | Delivery time: 1-2 business days

Price

Back to Top
Plant-based Biologics and Expression Systems Market by Type of Product (Biosimilars, Cell Therapies, Gene Therapies, Monoclonal Antibodies, Vaccines and Others), Type of Plant, Type of Service, Type of Expression System
Published: February 28, 2022
Roots Analysis
Content info: 155 Slides
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Title:
Plant-based Biologics and Expression Systems
Market by Type of Product (Biosimilars, Cell Therapies, Gene Therapies, Monoclonal Antibodies, Vaccines and Others), Type of Plant, Type of Service, Type of Expression System, Type of Target Disease Indication , Type of Therapeutic Area, Drug, and Region: Industry Trends and Global Forecasts, 2022-2035.

Example Insights:

Overview:

At present, biotechnology companies are on the look-out for cost-effective solutions such as plant-based expression systems, in order to support their research and manufacturing initiatives - Chief Project Manager, Business Development & Co-Founder, Europe-based mid-sized Company.

A significant rise in the popularity of biologics has been observed over the years. The demand for such treatment modalities further witnessed a surge post the onset of the COVID-19 pandemic. At present, about 85% of the drug candidates are produced using mammalian cell cultures. However, such systems are associated with a number of challenges; these include risk of introducing pathogens, concerns related to scale-up, decrease in productivity and rise in byproduct formation. It is also worth highlighting that research indicates that the existing mammalian cell capacities are likely to fulfill only 50% of the inflated demand (due to COVID-19)for biologics. In this context, owing to some major advances in synthetic organic chemistry, plant based expression systems have emerged as a promising alternative for the development of biologics. It is worth mentioning that plant-host engineering allows the production of proteins with distinct and uniform post-translational modifications, allowing the development of biologics, which demonstrate higher effectiveness, as compared to those produced using other protein expression systems, such as mammalian or yeast-based cell cultures. Plant-based biologics are safer, as they pose negligible risk of introducing human and animal pathogens in the therapy candidates. Additionally, plant molecular farming has the ability to facilitate rapid (4-8 weeks) plant-based biologics manufacturing at a large scale (several grams), as well as to meet the emergency demands (as observed in the case of COVID-19 pandemic). Moreover, the running costs of a GMP plant-based manufacturing facility are reported to be 25% less than those using other expression systems.

Given the aforementioned factors, pharmaceutical players are actively adopting plant-based expression systems for the production of various recombinant proteins. A wide range of vaccine candidates, plant-based enzymes, therapeutic proteins (including monoclonal antibodies) and nutritional proteins have also been produced via transgenic and transient expression in entire plants or plant cell cultures. Currently, close to 50 plant-based therapies have been developed / are being evaluated and more than 35 plant-based expression system providers are actively offering their proprietary technologies to drug developers. Multiple partnerships between industry and non-industry stakeholders, focused on the development of plant-based therapies, have been established. Driven by increasing prevalence of disease indications, growing demand for biologics, the ongoing efforts being carried out to advance the development of such products, as well as further optimize the associated technologies, the global plant-based biologics market is likely to grow at a healthy rate, in the foreseen future.

Scope of the Report:

The "Plant-based Biologics and Expression Systems Market by Type of Product (Biosimilars, Cell Therapies, Gene Therapies, Monoclonal Antibodies, Vaccines and Others), Type of Plant (Algae, Barley, Benth, Duckweed, Lettuce, Maize, Moss, Rice, Tomato, Tobacco and Wheat Germ), Type of Service (Research and Development, Manufacturing, Fill / Finish and Others), Type of Expression System (Stable Expression System and Transient Expression System), Type of Target Disease Indication (Cirrhotic Ascites, COVID-19, Cystic Fibrosis, Ebola Virus Infection, Fabry Disease, Gaucher Disease, Liver Cirrhosis, Influenza, and Peanut Allergy), Type of Therapeutic Area (Genetic Disorders, Infectious Disorders, Liver Disorders, Respiratory Disorders and Others), Drug (Elelyso, OsrHSA, PALFORZIA, PRX-110, PRX-102, Unnamed_1, Unnamed_2 and ZMapp), and Region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2022-2035" report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of plant-based therapies in the pharmaceutical industry, over the next 13 years. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed overview of the current market landscape of plant-based expression system providers, including information on some relevant parameters such as the type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco, and wheat germ), type of product (antibodies (unspecified), biosimilars, cell therapies, gene therapies, monoclonal antibodies, proteins (unspecified), vaccines and others), type of service (R&D, manufacturing, fill / finish, and others) and type of expression system (transient and stable). Additionally, it highlights information on plant-based expression system providers, including details related to their respective year of establishment, company size (in terms of employee count), location of headquarters and number of proprietary technologies.
  • A detailed overview of the current market landscape of plant-based biologics, including information on their status of development (marketed, clinical and preclinical), target disease indication (cirrhotic ascites, COVID-19, cystic fibrosis, Ebola virus infection, Fabry disease, Gaucher Disease, liver cirrhosis, influenza, and peanut allergy), therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders, and others) and type of product (antibodies (unspecified), biosimilars, cell therapies, monoclonal antibodies, proteins (unspecified), vaccines and others). Additionally, it highlights the developers of these novel therapeutics, including details on their year of establishment, company size (in terms of employee count), location of headquarters and number of proprietary drug candidates.
  • Elaborate profiles of key players engaged in providing plant-based expression system technologies to drug developers. Each profile features a brief overview of the company, details related to its technology portfolio, recent developments, and an informed future outlook.
  • An analysis of the recent partnerships and collaborations that have been inked between various stakeholders in the domain, during the period between 2017 and 2021, covering R&D agreements, licensing agreements, commercialization agreements, product development agreements, product development and manufacturing agreement, acquisitions and others.
  • An insightful company competitiveness analysis, including a 2*2 matrix comparing the key players engaged in offering plant-based expression systems, based on several relevant parameters (such as company experience, portfolio strength, partnership activity and company size). It also includes a benchmarking analysis of systems providers based on their portfolio strength and partnership activity.
  • An insightful publication analysis, which includes analysis of more than 1,000 peer-reviewed scientific articles related to plant-based biologics, published between 2000-2021, highlighting the research focus within this niche industry segment. Additionally, it features key trends observed across the aforementioned publications, including analysis based on several relevant parameters, such as year of publication, type of article, journal title, primary funding body, publisher, primary author, journal impact factor and key timelines. Further, it includes a multivariate publication attractiveness analysis based on various parameters, such as type of article, grant support, journal impact factor and timeline of publications.

One of the key objectives of the report was to estimate the existing size and the future opportunity associated with the plant-based biologics and expression systems market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates, expected pricing and R&D expenditure, we have provided informed estimates on the financial evolution of the market for the period 2022-2035. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of product (biosimilars, cell therapies, gene therapies, monoclonal antibodies, vaccines and others [B] type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco and wheat germ), [C] type of service (research and development, manufacturing, fill / finish and others), [D] type of expression system (stable expression system and transient expression system) [E] target disease indication (cirrhotic ascites, COVID-19, cystic fibrosis, Ebola virus infection, Fabry disease, Gaucher disease, liver cirrhosis, influenza, and peanut allergy) [F] therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders and others) [G] drug (Elelyso, OsrHSA, PALFORZIA, PRX-110, PRX-102, Unnamed_1, Unnamed_2 and ZMapp) and [H] region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World). In order to account for future uncertainties and to add robustness to our forecast model, we have provided three forecast scenarios, portraying the conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the key players engaged in providing plant-based expression systems?
  • What are the key plant sources utilized by drug developers to manufacture plant-based biologics?
  • Which are the key therapeutic areas for which plant-based biologics are being developed?
  • What are the different proprietary technologies of plant-based expression system providers?
  • What type of partnership models are most commonly adopted by stakeholders engaged in this domain?
  • What is the relative competitiveness of different plant-based expression system providers?
  • What is the evolving trend related to the focus of publications related to plant-based biologics?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of plant-based biologics and expression systems market and its likely evolution in the coming future.

Chapter 3 is an introductory chapter that highlights important concepts related to plant-based expression system providers. The chapter features information on classification of plant-based expression platforms and their associated advantages. Additionally, it includes a discussion on the commonly used plant-based bioproduction systems and mechanism of plant expression platforms. Further, it features details related to several recent developments observed in this domain.

Chapter 4 includes information on more than 35 plant-based expression system providers. It features a detailed analysis on current market landscape of plant-based expression system providers, including type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco, and wheat germ), type of product, type of service (R&D, manufacturing, fill / finish, and others) and type of expression system (transient and stable). Additionally, the chapter features developers' landscape, along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters and number of proprietary technologies.

Chapter 5 includes information on more than 45 plant-based biologics. It features a detailed analysis on current market landscape of plant-based biologics, including information on status of development (marketed, clinical and preclinical), target disease indication, therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders, and others), type of product (antibodies (unspecified), biosimilars, cell therapies, monoclonal antibodies, proteins (unspecified), vaccines and others). The chapter also features developers' landscape, along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters and number of proprietary drug candidates.

Chapter 6 features elaborate profiles of the prominent players engaged in providing plant-based expression system technologies to drug developers. Each profile features a brief overview of the company, details related to technology portfolio, recent developments, and an informed future outlook.

Chapter 7 presents an analysis on recent collaborations and partnerships that have been inked by several stakeholders in this domain, during the period 2017-2021, covering R&D agreements, licensing agreements, commercialization agreements, product development agreements, product development and manufacturing agreement, acquisitions, and others.

Chapter 8 presents a detailed company competitiveness analysis, including a 2*2 matrix comparing the key players engaged in the domain of plant-based expression systems, based on several relevant parameters (such as company experience, portfolio strength, partnership activity and company size). In addition, it features a spider web representation illustrating benchmarking of players based on portfolio strength and partnership activity of key players.

Chapter 9 presents an insightful analysis of more than 1,000 peer-reviewed scientific articles related to plant-based biologics, published between 2000-2021, highlighting the research focus within this niche industry segment. It also features, key trends observed across the aforementioned publications including analysis based on several relevant parameters, such as year of publication, type of article, journal title, primary funding body, publisher, primary author, journal impact factor and analysis based on timeline. Further, the chapter also highlights a multivariate publication attractiveness analysis based on various parameters such as type of article, grant support, journal impact factor and timeline of publications.

Chapter 10 presents a detailed market forecast analysis, highlighting the current market size and the future growth potential associated with plant-based expression system market, during the period 2022-2035. Additionally, the chapter provides the likely distribution of the current and forecasted opportunity based on type of product (biosimilars, cell therapies, gene therapies, monoclonal antibodies, vaccines, and others). type of plant (algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco, and wheat germ), type of service (research and development, manufacturing, fill / finish, and others), type of expression system (stable expression system and transient expression system), region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World).

Chapter 11 presents a detailed market forecast analysis, highlighting the current market size and the future growth potential associated with the plant-based biologics market, during the period 2022-2035. The chapter also provides the likely distribution of the current and forecasted opportunity based on type of target disease indication (cirrhotic ascites, COVID-19, cystic fibrosis, Ebola virus infection, Fabry disease, Gaucher disease, liver cirrhosis, influenza, and peanut allergy), type of therapeutic area (genetic disorders, infectious disorders, liver disorders, respiratory disorders and others), drug (Elelyso, OsrHSA, PALFORZIA, PRX-110, PRX-102, Unnamed_1, Unnamed_2 and ZMapp) and region (North America, Europe, Asia and Rest of the World).

Chapter 12 summarizes the entire report. It represents key takeaways and summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 13 is a collection of executive insights of the discussions that were held with various key stakeholders in this market.

Chapter 14 is an appendix, which provides tabulated data and numbers for all figures provided in the report.

Chapter 15 is an appendix, which comprises of the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Overview of Plant-based Biologics and Expression Systems
  • 3.2. Classification of Plant-based Expression Platforms
  • 3.3. Advantages of Plant-based Bioproduction Systems
  • 3.4. Commonly used Plant-based Bioproduction Systems
  • 3.5. Mechanism of Plant Expression Platform
  • 3.6. Recent Developments
  • 3.7. Future Perspective

4. PLANT-BASED EXPRESSION SYSTEMS: MARKET LANDSCAPE

  • 4.1. Plant-based Expression Systems: Market Landscape
  • 4.2. Plant-based Expression Systems: List of Providers
    • 4.2.1. Analysis by Type of Plant
    • 4.2.2. Analysis by Type of Biologic
    • 4.2.3. Analysis by Type of Plant and Type of Biologic
    • 4.2.4. Analysis by Type of Biologic and Region
    • 4.2.5. Analysis by Type of Plant, Type of Biologic and Region
    • 4.2.6. Analysis by Type of Service
    • 4.2.7. Analysis by Year of Establishment
    • 4.2.8. Analysis by Company Size
    • 4.2.9. Analysis by Region (Country-wise)
    • 4.2.10. Analysis by Region (Continent-wise)

5. PLANT-BASED BIOLOGICS: MARKET LANDSCAPE

  • 5.1. Plant-based Biologics: Pipeline Review
  • 5.2. Plant-based Biologics: List of Drug Candidates
    • 5.2.1. Analysis by Status of Development
    • 5.2.2. Analysis by Target Disease Indication
    • 5.2.3. Analysis by Therapeutic Area
    • 5.2.4. Analysis by Status of Development and Therapeutic Area
    • 5.2.5. Analysis by Type of Product
    • 5.2.6. Analysis by Status of Development and Type of Product
  • 5.3. Plant-based Biologics: List of Drug Developers
    • 5.3.1. Analysis by Year of Establishment
    • 5.3.2. Analysis by Company Size
    • 5.3.3. Analysis by Region
      • 5.3.3.1. Analysis of Developers in North America
      • 5.3.3.2. Analysis of Developers in Europe
      • 5.3.3.3. Analysis of Developers in Rest of the World

6. COMPANY PROFILES

  • 6.1. Medicago
    • 6.1.1. Company Overview
    • 6.1.2. Technology Portfolio
    • 6.2.3. Recent Developments and Future Outlook
  • 6.2. Leaf Expression Systems
    • 6.2.1. Company Overview
    • 6.2.2. Technology Portfolio
    • 6.2.3. Recent Developments and Future Outlook
  • 6.3. Eleva
    • 6.3.1. Company Overview
    • 6.3.2. Technology Portfolio
    • 6.3.3. Recent Developments and Future Outlook
  • 6.4. iBIO
    • 6.4.1. Company Overview
    • 6.4.2. Technology Portfolio
    • 6.4.3. Recent Developments and Future Outlook
  • 6.5. PlantForm
    • 6.5.1. Company Overview
    • 6.5.2. Technology Portfolio
    • 6.5.3. Recent Developments and Future Outlook
  • 6.6. G+Flas Life Sciences
    • 6.6.1. Company Overview
    • 6.6.2. Technology Portfolio
    • 6.6.3. Recent Developments and Future Outlook
  • 6.7. Kentucky Bioprocessing
    • 6.7.1. Company Overview
    • 6.7.2. Technology Portfolio
    • 6.7.3. Recent Developments and Future Outlook
  • 6.8. Kentucky Bioprocessing
    • 6.8.1. Company Overview
    • 6.8.2. Technology Portfolio
    • 6.8.3. Recent Developments and Future Outlook
  • 6.9. Angany
    • 6.9.1. Company Overview
    • 6.9.2. Technology Portfolio
    • 6.9.3. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS

  • 7.1. Plant-based Biologics and Expression Systems: Partnerships and Collaborations
    • 7.1.1. Analysis by Year of Partnership
    • 7.1.2. Analysis by Type of Partnership
    • 7.1.3. Analysis by Year and Type of Partnership
    • 7.1.4. Analysis by Type of Biologic
    • 7.1.5. Analysis by Type of Partnership and Type of Biologic
    • 7.1.6. Key Players: Analysis by Number of Partnerships
    • 7.1.7. Analysis by Partner Headquarters (Region)
    • 7.1.8. Analysis by Region and Type of Agreement
    • 7.1.9. Intercontinental and Intracontinental Deals

8. COMPANY COMPETITIVENESS ANALYSIS

  • 8.1. Plant-based Expression System Providers: Company Competitiveness Analysis
  • 8.2. Assumptions and Key Parameters
  • 8.3. Methodology
  • 8.4. Benchmarking of Portfolio Strength
  • 8.5. Benchmarking of Partnership Strength
  • 8.6. Company Competitiveness Analysis: Small Companies
  • 8.7. Company Competitiveness Analysis: Mid-sized Companies
  • 8.8. Company Competitiveness Analysis: Large Companies

9. PUBLICATIONS ANALYSIS

  • 9.1. Plant-based Biologics and Expression Systems: Publications Analysis
  • 9.2. Assumptions and Key Parameters
  • 9.3. Methodology
    • 9.3.1. Analysis by Year of Publication
    • 9.3.2. Analysis by Article Type
    • 9.3.3. Analysis by Journal Title
    • 9.3.4. Analysis by Grant Awarded
    • 9.3.5. Analysis by Primary Funding Body
    • 9.3.6. Analysis by Publisher
    • 9.3.7. Analysis by Primary Author
    • 9.3.8. Analysis by Journal Impact Factor
    • 9.3.9. Analysis by Timeline of Approval
      • 9.3.9.1. Analysis by Article Type and Timeline of Receival, Acceptance and Approval
      • 9.3.9.2. Analysis by Journal Impact Factor and Timeline of Receival, Acceptance and Approval
      • 9.3.9.3. Analysis by Grant Awarded and Timeline of Receival, Acceptance and Approval
    • 9.3.10. Benchmarking Analysis

10. PLANT-BASED EXPRESSION SYSTEMS: MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 10.1. Key Assumptions and Forecast Methodology
  • 10.2. Global Plant-based Expression Systems Market, 2022-2035
  • 10.3. Plant-based Expression Systems Market: Analysis by Product, 2022 and 2035
    • 10.3.1. Plant-based Expression Systems Market for Biosimilars, 2022-2035
    • 10.3.2. Plant-based Expression Systems Market for Cell Therapies, 2022-2035
    • 10.3.3. Plant-based Expression Systems Market for Gene Therapies, 2022-2035
    • 10.3.4. Plant-based Expression Systems Market for Monoclonal Antibodies, 2022-2035
    • 10.3.5. Plant-based Expression Systems Market for Vaccines, 2022-2035
    • 10.3.6. Plant-based Expression Systems Market for Others, 2022-2035
  • 10.4. Plant-based Expression Systems Market: Analysis by Plant, 2022 and 2035
    • 10.4.1. Plant-based Expression Systems Market for Algae, 2022-2035
    • 10.4.2. Plant-based Expression Systems Market for Barley, 2022-2035
    • 10.4.3. Plant-based Expression Systems Market for Benth, 2022-2035
    • 10.4.4. Plant-based Expression Systems Market for Duckweed, 2022-2035
    • 10.4.5. Plant-based Expression Systems Market for Lettuce, 2022-2035
    • 10.4.6. Plant-based Expression Systems Market for Maize, 2022-2035
    • 10.4.7. Plant-based Expression Systems Market for Moss, 2022-2035
    • 10.4.8. Plant-based Expression Systems Market for Rice, 2022-2035
    • 10.4.9. Plant-based Expression Systems Market for Tomato, 2022-2035
    • 10.4.10. Plant-based Expression Systems Market for Tobacco, 2022-2035
    • 10.4.11. Plant-based Expression Systems Market for Wheat Germ, 2022-2035
  • 10.5. Plant-based Expression Systems Market: Analysis by Type of Service, 2022 and 2035
    • 10.5.1. Plant-based Expression Systems Market for Research and Development, 2022-2035
    • 10.5.2. Plant-based Expression Systems Market for Manufacturing, 2022-2035
    • 10.5.3. Plant-based Expression Systems Market for Fill / Finish, 2022-2035
    • 10.5.4. Plant-based Expression Systems Market for Others, 2022-2035
  • 10.6. Plant-based Expression Systems Market: Analysis by Expression System, 2022 and 2035
    • 10.6.1. Plant-based Expression Systems Market for Stable Expression System, 2022-2035
    • 10.6.2. Plant-based Expression Systems Market for Transient Expression System, 2022-2035
  • 10.7. Plant-based Expression Systems Market: Analysis by Region, 2022 and 2035
    • 10.7.1. Plant-based Expression Systems Market in North America, 2022-2035
    • 10.7.2. Plant-based Expression Systems Market in Europe, 2022-2035
    • 10.7.3. Plant-based Expression Systems Market in Asia, 2022-2035
    • 10.7.4. Plant-based Expression Systems Market in Latin America, 2022-2035
    • 10.7.5. Plant-based Expression Systems Market in MENA, 2022-2035
    • 10.7.6. Plant-based Expression Systems Market in Rest of the World, 2022-2035

11. PLANT-BASED BIOLOGICS: MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 11.1. Key Parameters and Assumptions
  • 11.2. Forecast Methodology
  • 11.3. Global Plant-based Biologics Market, 2022-2035
  • 11.4. List of Forecasted Drugs
    • 11.4.1. Elelyso, Protalix Biotherapeutics
      • 11.4.1.1. Sales Forecast
      • 11.4.1.2. Net Present Value
      • 11.4.1.3 Value Creation Analysis
    • 11.4.2. OsrHSA, Healthgen Biotechnology
      • 11.4.2.1 Sales Forecast
      • 11.4.2.2. Net Present Value
      • 11.4.2.3. Value Creation Analysis
    • 11.4.3. PALFORZIA, Aimmune Therapeutics
      • 11.4.3.1. Sales Forecast
      • 11.4.3.2. Net Present Value
      • 11.4.3.3. Value Creation Analysis
    • 11.4.4. PRX-110, Protalix Biotherapeutics
      • 11.4.4.1. Sales Forecast
      • 11.4.4.2. Net Present Value
      • 11.4.4.3. Value Creation Analysis
    • 11.4.5. PRX-102, Protalix Biotherapeutics
      • 11.4.5.1. Sales Forecast
      • 11.4.5.2. Net Present Value
      • 11.4.5.3. Value Creation Analysis
    • 11.4.6. Unnamed_1, Medicago
      • 11.4.6.1. Sales Forecast
      • 11.4.6.2. Net Present Value
      • 11.4.6.3. Value Creation Analysis
    • 11.4.7. Unnamed_2, Medicago
      • 11.4.7.1. Sales Forecast
      • 11.4.7.2. Net Present Value
      • 11.4.7.3. Value Creation Analysis
    • 11.4.8. ZMapp, Mapp Biopharmaceutical
      • 11.4.8.1. Sales Forecast
      • 11.4.8.2. Net Present Value
      • 11.4.8.3. Value Creation Analysis
  • 11.5. Global Plant-based Biologics Market: Analysis by Target Disease Indication, 2022 and 2035
    • 11.5.1. Plant-based Biologics Market for Cirrhotic Ascites, 2022-2035
    • 11.5.2. Plant-based Biologics Market for COVID-19, 2022-2035
    • 11.5.3 Plant-based Biologics Market for Cystic Fibrosis, 2022-2035
    • 11.5.4 Plant-based Biologics Market for Ebola Virus Infection, 2022-2035
    • 11.5.5. Plant-based Biologics Market for Fabry Disease, 2022-2035
    • 11.5.6. Plant-based Biologics Market for Gaucher Disease, 2022-2035
    • 11.5.7. Plant-based Biologics Market for Influenza, 2022-2035
    • 11.5.8. Plant-based Biologics Market for Liver Cirrhosis, 2022-2035
    • 11.5.9. Plant-based Biologics Market for Peanut Allergy, 2022-2035
  • 11.6. Plant-based Biologics Market: Analysis by Therapeutic Area, 2022 and 2035
    • 11.6.1. Plant-based Biologics Market for Genetic Disorders, 2022-2035
    • 11.6.2 Plant-based Biologics Market for Infectious Disorders, 2022-2035
    • 11.6.3 Plant-based Biologics Market for Liver Disorders, 2022-2035
    • 11.6.4. Plant-based Biologics Market for Respiratory Disorders, 2022-2035
    • 11.6.5. Plant-based Biologics Market for Others, 2022-2035
  • 11.7. Plant-based Biologics Market: Analysis by Region, 2022 and 2035
    • 11.7.1. Plant-based Biologics Market in North America, 2022-2035
    • 11.7.2. Plant-based Biologics Market in Europe, 2022-2035
    • 11.7.3. Plant-based Biologics Market in Asia, 2022-2035
    • 11.7.4. Plant-based Biologics Market in Rest of the World, 2022-2035

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

  • 13.1. Transactiva
    • 13.1.1. Company Snapshot
    • 13.1.2. Interview Transcript: Sara Raccovelli (Researcher)
  • 13.2. ORF Genetics
    • 13.2.1. Company Snapshot
    • 13.2.2. Interview Transcript: Júlíus B Kristinsson (Chief Project Manager, Business Development & Co-Founder)

14. APPENDIX 1: TABULATED DATA

15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Tables

  • Table 4.1 List of Plant-based Expression System Providers
  • Table 5.1 Plant-based Biologics: List of Drug Candidates
  • Table 5.2 Plant-based Biologics Developers: List of Drug Developers
  • Table 7.1 Plant-based Biologics and Expression Systems: Partnerships and Collaborations
  • Table 10.1 Global Plant-based Expression Systems Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.2 Plant-based Expression Systems Market: Analysis by Product, 2022 and 2035
  • Table 10.3 Plant-based Expression Systems Market for Biosimilars, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.4 Plant-based Expression Systems Market for Cell Therapies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.5 Plant-based Expression Systems Market for Gene Therapies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.6 Plant-based Expression Systems Market for Monoclonal Antibodies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.7 Plant-based Expression Systems Market for Vaccines, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.8 Plant-based Expression Systems Market for Others, Conservative, Base and Optimistic, 2022-2035 (USD Million)
  • Table 10.9 Plant-based Expression Systems Market: Analysis by Plant, 2022 and 2035
  • Table 10.10 Plant-based Expression Systems Market for Algae, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.11 Plant-based Expression Systems Market for Barley, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.12 Plant-based Expression Systems Market for Benth, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.13 Plant-based Expression Systems Market for Duckweed, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.14 Plant-based Expression Systems Market for Lettuce, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.15 Plant-based Expression Systems Market for Maize, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.16 Plant-based Expression Systems Market for Moss, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.17 Plant-based Expression Systems Market for Rice, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.18 Plant-based Expression Systems Market for Tomato, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.19 Plant-based Expression Systems Market for Tobacco, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.20 Plant-based Expression Systems Market for Wheat Germ, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.21 Plant-based Expression Systems Market: Analysis by Type of Service, 2022 and 2035
  • Table 10.22 Plant-based Expression Systems Market for Research and Development, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.23 Plant-based Expression Systems Market for Manufacturing, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.24 Plant-based Expression Systems Market for Fill / Finish, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.25 Plant-based Expression Systems Market for Others, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.26 Plant-based Expression Systems Market: Analysis by Expression System, 2022 and 2035
  • Table 10.27 Plant-based Expression Systems Market for Stable Expression System, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.28 Plant-based Expression Systems Market for Transient Expression System, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.29 Plant-based Expression Systems Market: Analysis by Region, 2022 and 2035
  • Table 10.30 Plant-based Expression Systems Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.31 Plant-based Expression Systems Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.32 Plant-based Expression Systems Market in Asia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.33 Plant-based Expression Systems Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.34 Plant-based Expression Systems Market in MENA, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 10.35 Plant-based Expression Systems Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.1 List of Forecasted Drugs
  • Table 11.2 Elelyso, Protalix Biotherapeutics, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.3 OsrHSA, Healthgen Biotechnology, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.4 PALFORZIA, Aimmune Therapeutics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.5 PRX-110, Protalix Biotherapeutics, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.6 PRX-102, Protalix Biotherapeutics, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.7 Unnamed_1, Medicago, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.8 Unnamed_2, Medicago, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.9 ZMapp, Mapp Biopharmaceutical, Sales Forecast, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.10 Global Plant-based Biologics Market: Analysis by Target Disease Indication, 2022 and 2035
  • Table 11.11 Plant-based Biologics Market for Cirrhotic Ascites, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.12 Plant-based Biologics Market for COVID-19, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.13 Plant-based Biologics Market for Cystic Fibrosis, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.14 Plant-based Biologics Market for Ebola Virus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.15 Plant-based Biologics Market for Fabry Disease, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.16 Plant-based Biologics Market for Gaucher Disease, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.17 Plant-based Biologics Market for Influenza, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.18 Plant-based Biologics Market for Liver Cirrhosis, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.19 Plant-based Biologics Market for Peanut Allergy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.20 Plant-based Biologics Market: Analysis by Therapeutic Area, 2022 and 2035
  • Table 11.21 Plant-based Biologics Market for Genetic Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.22 Plant-based Biologics Market for Infectious Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.23 Plant-based Biologics Market for Liver Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.24 Plant-based Biologics Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.25 Plant-based Biologics Market for Others, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.26 Plant-based Biologics Market: Analysis by Region, 2022 and 2035
  • Table 11.27 Plant-based Biologics Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.28 Plant-based Biologics Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.29 Plant-based Biologics Market in Asia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 11.30 Plant-based Biologics Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. Agrenvec
  • 2. Angany
  • 3. Australian National University (ANU)
  • 4. atbtherapeutics
  • 5. AzarGen Biotechnologies
  • 6. Baiya Phytopharm
  • 7. BC Partners
  • 8. BGM Pharmaceuticals
  • 9. Bill and Melinda Gates Foundation
  • 10. Bio-Manguinhos
  • 11. Oswaldo Cruz Foundation (Fiocruz)
  • 12. BioMed Central
  • 13. Caliber Biotherapeutics
  • 14. Cape Biologix Technologies
  • 15. Carnegie Corporation of New York
  • 16. CC-Pharming (Also known as Ruicheng Haihui Biotechnology)
  • 17. CellFree Sciences
  • 18. Chiesi Farmaceutici
  • 19. Corteva Agriscience
  • 20. Council for Scientific and Industrial Research (CSIR)
  • 21. Creative Biolabs
  • 22. Defence Research & Development Canada
  • 23. Defyrus
  • 24. Dow AgroSciences
  • 25. Dynavax Technologies
  • 26. EdgePoint AI
  • 27. Eleva
  • 28. Elsevier
  • 29. ERS Genomics
  • 30. Eversea
  • 31. Fraunhofer Society
  • 32. Frontiers
  • 33. G+FLAS Life Sciences
  • 34. GenScript
  • 35. GlaxoSmithKline
  • 36. Government of Canada
  • 37. Healthgen Biotechnology
  • 38. HotHouse BioEngineering
  • 39. iBio
  • 40. Icon Genetics
  • 41. Inno-3B
  • 42. John Wiley and Sons
  • 43. Kentucky Bioprocessing
  • 44. Leaf Expression Systems
  • 45. LenioBio
  • 46. Lincoln Diagnostics
  • 47. Lung Biotechnology
  • 48. McMaster University
  • 49. MDPI
  • 50. Medicago
  • 51. National Collaborative Research Infrastructure Strategy
  • 52. Australian Plant Phenomics Facility
  • 53. National Institute of Allergy and Infectious Diseases
  • 54. National Institute of General Medical Sciences
  • 55. National Natural Science Foundation of China
  • 56. Nature Publishing
  • 57. National Institutes of Health
  • 58. Nomad Bioscience
  • 59. ORF Genetics
  • 60. Oxford University Press
  • 61. PBL Technology
  • 62. Pfizer
  • 63. Phylloceuticals
  • 64. PlantForm
  • 65. Poliomyelitis Research Foundation
  • 66. POSCO
  • 67. ProdiGene
  • 68. Profacgen
  • 69. Protalix Biotherapeutics
  • 70. Public Library of Science
  • 71. RubrYc Therapeutics
  • 72. Safi Biosolutions
  • 73. Samabriva
  • 74. SarcoMed USA
  • 75. Sigma-Aldrich
  • 76. Solarvest BioEnergy
  • 77. St George's University of London
  • 78. Synthon
  • 79. Takara Bio
  • 80. Transactiva
  • 81. US Department of Defense
  • 82. Unibio
  • 83. Universite? de Montre?al
  • 84. University of Alberta
  • 85. University of Guelph
  • 86. University of Wisconsin-Madison
  • 87. Ventria Bioscience
  • 88. Wilfrid Laurier University
  • 89. Zea Biosciences
  • 90. Zukunftsfonds Heilbronn